Introduction {#S0001}
============

Anticoagulation therapy with warfarin is highly effective at reducing thromboembolic events (TE), but is associated with a higher risk of major bleeding compared to new oral anticoagulants \[antithrombotic drugs -- Xa (rivaroxaban, apixaban) and IIa inhibitors (dabigatran)\] \[[@CIT0001], [@CIT0002]\]. They appear to have a favorable safety profile, particularly with the decreased risk for intracranial bleeding \[[@CIT0003]\]. However, the clinical decision on antithrombotic management should be based on the balance between an individual\'s thromboembolic and hemorrhagic risk. The most commonly used scheme to determine this risk of TE in patients with nonvalvular atrial fibrillation (AF) was the CHADS2 score \[[@CIT0004]\]. A limitation of this scale was a large part of the eligibility of patients as intermediate risk and skipping other potential risk factors for TE, such as myocardial infarction, complex aortic plaque, peripheral artery disease, female sex and age 65-74. The additional risk factors have been expressed in the CHA2DS2-VASc score \[[@CIT0004]\]. Finally in current guidelines, the CHA2DS2-VASc score is crucial to decide whether or not to anticoagulate \[[@CIT0005]\].

Anticoagulant therapy carries a risk of bleeding, and major bleeding such as intracranial bleeds can be catastrophic. The HAS-BLED score is a simple and user-friendly tool for the assessment of bleeding risk before starting anticoagulation \[[@CIT0004]\]. A HAS-BLED score of 3 points or more indicates increased one-year bleed risk on anticoagulation sufficient to justify caution or more regular review. That risk includes intracranial bleeding, bleeding requiring hospitalization, one with a hemoglobin drop \> 2 g/l or one that needs transfusion \[[@CIT0006]\].

The aim of the study was to evaluate in 'real life' risk stratification scores in patients with nonvalvular sustained AF who have not yet received anticoagulation.

Material and methods {#S0002}
====================

From 81 consecutive patients with the inclusion criterion as sustained nonvalvular AF, who had not been treated with anticoagulants, finally 68 were enrolled in the study. Patients with unstable arterial hypertension (\> 160/110 mm Hg), alcohol abuse, a serious incident of bleeding requiring blood transfusion, bleeding disorder, liver disease (ALT \> 3 times the upper reference level), and those who did not agree to further contact were excluded from the study (*n* = 13) ([Fig. 1](#F0001){ref-type="fig"}).

![Recruitment patients for the study](KITP-11-22545-g001){#F0001}

We collected the following data: demographic (age, sex), clinical (concomitant diseases, medications, a history of thromboembolic and bleeding events), and basic laboratory (morphology, electrolytes, GFR, glucose, lipids, liver enzymes, bilirubin, C-reactive protein). A follow-up was performed to ascertain outcomes: clinical events (stroke/TIA, peripheral embolism, bleeding), change in antithrombotic therapy (discontinuation, duration on therapy); medical history update; and INR records in relation to therapeutic range. Hemorrhage included major and minor bleeding. Major bleeding was defined as an intracranial hemorrhage, a decrease in blood hemoglobin level of more than 5.0 g/dl, the need for a transfusion of two or more units of blood, the need for corrective surgery, or any combination of these events. Minor bleeding was defined as a subcutaneous ecchymosis or hematoma, gastrointestinal bleeding, urinary bleeding or bloody sputum. Hypertension, diabetes, and lipid disorders were diagnosed according to the latest recommendations, as well as the implementation of antiplatelet therapy.

For each patient CHADS2 and CHA2DS2-VASc scores were calculated. The CHADS2 score is based on a point system in which 2 points are assigned for a history of stroke or TIA and 1 point each is assigned for age ≥ 75 years, a history of hypertension, diabetes, or recent cardiac failure \[[@CIT0004]\]. The CHA2DS2-VASc scale gives two points for age of ≥ 75 years, and in addition to factors of the CHADS2 score, one point each for age 65-74 years, vascular disease, and female sex ([Table I](#T0001){ref-type="table"}) \[[@CIT0004]\]. The bleeding risk of our patients was assessed by the HAS-BLED score \[assigning one point each for the presence of hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition (e.g. bleeding diathesis, anemia), labile INR (International Normalized Ratio), elderly (\> 65 years), and drugs/alcohol concomitantly\] \[[@CIT0004]\].

###### 

Risk factors for stroke and thrombo-embolism in non-valvular AF according to CHADS2 and CHA2DS2-VASc score \[[@CIT0004]\]

           Condition                                    Points           Condition                                    Points
  -------- -------------------------------------------- -------- ------- -------------------------------------------- --------
  **C**    Congestive heart failure                     1        **C**   Congestive heart failure                     1
  **H**    Hypertension                                 1        **H**   Hypertension                                 1
  **A**    Age \> 75 years                              1        **A**   Age \> 75 years                              2
  **D**    Diabetes                                     1        **D**   Diabetes                                     1
  **S**    Prior stroke or transient ischaemic attack   2        **S**   Prior stroke or transient ischaemic attack   2
                                                                 **V**   Vascular disease                             1
  **A**    Aged 65-74 years                             1                                                             
  **Sc**   Sex category (female)                        1                                                             

Initially, the risk of TE was calculated on the basis of the CHADS2 score. Next, in patients with CHADS2 \< 2 the risk of TE was re-estimated by the CHA2DS2-VASc score. Warfarin was indicated in patients at high risk for TE (CHADS2 or CHA2DS2-VASc ≥ 2), after consideration of the patient\'s decision.

Study groups were analyzed related to scores: CHADS2 ≥ 2 (group I, *n* = 35) vs. CHADS2 \< 2 and CHA2DS2-VASc score ≥ 2 (group II, *n* = 26) and gender.

The local Bioethics Committee approved the study and informed consent was obtained from all participants.

Statistical analysis {#S20003}
--------------------

Continuous variables are presented as mean values ± SD or medians with interquartile ranges (IQR) in case of their non-normal distribution. An independent *t*-test (when the distribution in both groups was normal) or the Mann-Whitney *U* test (in the absence of normal distribution of measured variables) was used to evaluate differences in the continuous factors between the groups. χ^2^ independent test was used to investigate the relationship between scores (CHADS2, CHA2DS2-VASc) and qualitative variables. Analysis was performed with Statistica version 9.0 software. *P* values \< 0.05 were considered to be statistically significant.

Results {#S0004}
=======

The baseline characteristics of patients are summarized in [Table II](#T0002){ref-type="table"}. The studied population consisted mainly of older patients, 21 patients (31%) were ≥ 75 years old and 18 (26%) were aged 65-74. Nineteen patients (27%) had experienced myocardial infarction, 10 (15%) stroke, 13 subjects (19%) had diabetes mellitus, and 5 (7%) peripheral artery disease. The most frequent was hypertension (73%), followed by dyslipidemia (72%) and coronary artery disease (42%). Patients had preserved left ventricular systolic function (mean 53 ±12%, median 56%) and no symptoms of heart failure.

###### 

Characteristics of the studied patients

  Parameter                                                        Mean     SD     Median   Minimum   Maximum   Q25     Q75
  ---------------------------------------------------------------- -------- ------ -------- --------- --------- ------- --------
  Age (years)[\*](#TF0001){ref-type="table-fn"}                    65.75    13.2   67       21        90        60.5    76
  BMI (kg/m^2^)[\*](#TF0001){ref-type="table-fn"}                  28.34    4.91   27.77    18.01     42.97     24.75   30.74
  CHADS2[\*](#TF0001){ref-type="table-fn"}                         1.76     1.16   2        0         5         1       2
  CHA2DS2-VASc[\*](#TF0001){ref-type="table-fn"}                   3.00     1.58   3        0         8         2       4
  HAS-BLED[\*](#TF0001){ref-type="table-fn"}                       0.99     0.63   1        0         3         1       1
  Dose of warfarin weekly (mg)[\*](#TF0001){ref-type="table-fn"}   31.66    11.8   35       8.75      56        21      35
  WBC (1000/µl)                                                    7.53     2.12   7.6      3.5       14.9      6       9
  RBC (m/µl)[\*](#TF0001){ref-type="table-fn"}                     4.59     0.54   4.6      3.64      6.06      4.12    4.92
  HGB (g/dl)                                                       13.85    1.52   13.95    9.7       17.2      12.7    14.8
  HCT (%)                                                          42.05    6.61   42.5     4.4       54.4      38.5    45.5
  PLT (1000/µl)                                                    219.45   91.2   206      83        647       167     245
  Na^+^ (mg/dl)                                                    138.1    2.47   138      133       145       137     140
  K^+^ (mg/dl)                                                     4.37     0.41   4.35     3.39      5.28      4.14    4.57
  GFR (ml/min/1.72 m^2^)                                           93.46    33.1   89.52    39.51     180.27    65.33   114.05
  Glucose (mmol/l)                                                 5.85     1.47   5.5      3.8       11.3      5       6.3
  TCh (mmol/l)                                                     4.59     1.25   4.3      2.4       8         3.6     5.35
  LDL (mmol/l)                                                     2.62     1.16   2.45     0.7       6         1.6     3.5
  HDL (mmol/l)                                                     1.33     0.34   1.30     0.63      2.23      1.09    1.56
  TG (mmol/l)                                                      1.37     0.56   1.26     0.55      3.33      1.02    1.71
  ALT (UI/l)[\*](#TF0001){ref-type="table-fn"}                     26.40    13.9   23       10        94        18      31
  AST (UI/l)[\*](#TF0001){ref-type="table-fn"}                     24.69    8.31   23       11        62        19      28
  Bilirubin µmol/l[\*](#TF0001){ref-type="table-fn"}               13.10    7.13   11.15    0.5       36        8.35    16.7
  CRP (mg/dl)[\*](#TF0001){ref-type="table-fn"}                    7.46     10.8   3.1      0.2       45        1.2     6.7

Non-normal distribution

BMI -- body mass index; WBC -- white blood cells; RBC -- red blood cells; HGB -- hemoglobin; HCT -- hematocrit; PLT -- platelets; Na^+^ -- sodium; K^+^ -- potassium; Cl^−^ -- chlorine; GFR -- glomerular filtration rate; TCh -- total cholesterol; LDL -- low density lipoproteins; HDL -- high density lipoproteins; TG -- triglycerides; ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; CRP -- C reactive protein; SD -- standard deviation; Q25 -- first quartile; Q75 -- third quartile

Almost half of patients were women (47%). Compared to men, women had significantly more often a history of ischemic stroke (2 vs. 18%, *p* = 0.03), but less coronary heart disease (58 vs. 25%, *p* = 0.005). Women had higher levels of HDL (1.47 vs. 1.21 mg/dl, *p* = 0.003), and lower hemoglobin (13.5 vs. 14.2 g/dl, *p* = 0.05) and hematocrit (40.4 vs. 43.4%, *p* = 0.02) than men. In analysis according to gender, the studied population did not differ in age, body mass index (BMI), daily doses of warfarin, scale HAS-BLED, high-sensitive C-reactive protein (hsCRP), and kidney and liver function ([Table III](#T0003){ref-type="table"}).

###### 

Characteristics according to gender and scales CHADS2 ≥ 2 (group I), and CHADS2 \< 2 and CHA2DS2-VASc ≥ 2 (group II)

  Parameter                                                       Group I       Group II      *P*          Men           Women         *P*
  --------------------------------------------------------------- ------------- ------------- ------------ ------------- ------------- -----------
  Age (years)[\*](#TF0002){ref-type="table-fn"}                   72.4 ± 10.3   62.9 ± 10.3   **0.0002**   67.2 ± 14.5   64.1 ± 11.9   0.223
  BMI (kg/m^2^)[\*](#TF0002){ref-type="table-fn"}                 28.6 ± 5.3    28.3 ± 4.9    0.902        28 ± 4.8      28.8 ± 5.0    0.459
  HAS-BLED[\*](#TF0002){ref-type="table-fn"}                      1.2 ± 0.7     0.8 ± 0.5     0.027        1.0 ± 0.51    0.9 ± 0.76    0.490
  Dose of warfarin daily (mg)[\*](#TF0002){ref-type="table-fn"}   4.5 ± 1.8     4.4 ± 1.6     0.777        4.6 ± 1.7     4.5 ± 1.8     0.888
  Dose of warfarin weekly (mg)\*                                  31.8 ± 12.3   30.8 ± 11.3   0.800        32.1 ± 11.5   31.1 ± 12.4   0.898
  GFR (ml/min/1.72 m^2^)[\*](#TF0002){ref-type="table-fn"}        79.8 ± 25.6   99.7 ± 30.7   **0.008**    92.9 ± 2.4    94.2 ± 34.6   0.875
  Glucose (mmol/l)[\*](#TF0002){ref-type="table-fn"}              6.1 ± 1.6     5.6 ± 1.5     0.274        5.7 ± 1.3     6.1 ± 1.7     0.225
  TCh (mmol/l)                                                    4.2 ± 0.9     5.0 ± 1.4     **0.011**    4.3 ± 1.2     4.9 ± 1.3     0.096
  LDL (mmol/l)                                                    2.3 ± 0.9     2.9 ± 1.3     **0.022**    2.5 ± 1.1     2.8 ± 1.2     0.254
  HDL (mmol/l)                                                    1.4 ± 0.31    1.4 ± 0.4     0.551        1.2 ± 0.2     1.5 ± 0.4     **0.003**
  TG (mmol/l)                                                     1.3 ± 0.51    1.4 ± 0.6     0.221        1.4 ± 0.7     1.3 ± 0.4     0.751
  ALT (IU/l)[\*](#TF0002){ref-type="table-fn"}                    24.5 ± 15.6   26.2 ± 10.1   0.069        25.2 ± 11.8   27.8 ± 16.1   0.536
  AST (IU/l)[\*](#TF0002){ref-type="table-fn"}                    24.1 ± 9.0    24.4 ± 6.6    0.421        24.6 ± 6.6    24.7 ± 10.0   0.511
  Bilirubin (µmol/l)[\*](#TF0002){ref-type="table-fn"}            11.6 ± 5.5    14.4 ± 8.0    0.391        13.5 ± 7.1    12.7 ± 7.3    0.491
  CRP (mg/dl)[\*](#TF0002){ref-type="table-fn"}                   6.1 ± 9.4     6.7 ± 9.7     0.614        9.2 ± 13.7    5.2 ± 4.4     0.522
  Stroke                                                          17.14         3.85          0.228        2.78          18.6          **0.030**
  CAD                                                             54.29         34.62         0.127        58.33         25.00         **0.005**
  Myocardial infarction                                           37.14         19.23         0.129        30.56         25.00         0.610
  Diabetes                                                        28.57         11.54         0.108        13.89         25.00         0.244
  Dyslipidemia                                                    77.14         69.23         0.487        77.78         65.63         0.264
  Hypertension                                                    88.57         65.38         0.028        75.00         71.88         0.770
  Bleeding                                                        17.14         11.54         0.541        8.33          18.75         0.364

The results are presented as% and mean value ± SD

Non-normal distribution

BMI -- body mass index; GFR -- glomerular filtration rate; TCH -- total cholesterol; LDL -- low density lipoproteins; HDL -- high density lipoproteins; TG -- triglycerides; ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; CRP -- C reactive protein; CAD -- coronary artery disease; SD -- standard deviation

Distribution of CHADS2 and CHA2DS2-VASc scores is shown in [Fig. 2](#F0002){ref-type="fig"}. For the total population the median CHADS2 score was 2 points and CHA2DS2-VASc 3. Taking into account the mentioned two scales 61 patients (90%) were at high risk for thromboembolic complications. In 26 patients (43%) with one point on CHADS2, qualifications for vitamin K antagonist (VKA) therapy was only possible by using CHA2DS2-VASc. In this group were 15 women (57%).

![Distribution of patients according to CHADS2 and CHA2DS2-VASc risk stratification](KITP-11-22545-g002){#F0002}

Seven patients (10%), all men, did not require anticoagulation (CHA2DS2-VASc = 0). In the studied population there were no patients with CHA2DS2-VASc = 1.

Concomitant aspirin and VKA was used by 42% and dual antiplatelet therapy by 16% of patients.

During the 18 ±2.35 months of follow-up the median daily dose of warfarin was 5 mg (range 1.25-8 mg) with therapeutically optimal INR.

The total study group was at low risk of bleeding, with a median HAS-BLED score of 1 (98% with HAS-BLED ≤ 2 \[low risk\]). Among hemorrhage events, there was no major bleeding. Minor bleeding was observed in 9 (13%) patients, including 6 women (67%): nose (5 cases), the urinary tract (3) and gastrointestinal tract (1). Three men with bleeding received one of the antiplatelet drugs.

During the 18 months of follow-up no incident of thromboembolic complication was recorded.

Patients of group II compared to group I were younger (*p* = 0.0002), with prevalence of women (58 vs. 43%, *p* = 0.25), and less frequently burdened with arterial hypertension (*p* = 0.03). In this group there were higher glomerular filtration rate (*p* = 0.008), total cholesterol level (*p* = 0.01) and LDL values (*p* = 0.02). Moreover, group II patients had a lower value of HAS-BLED (*p* = 0.03). The characteristics of the studied groups are presented in [Table III](#T0003){ref-type="table"}.

Discussion {#S0005}
==========

The main finding of our study is that the CHA2DS2-VASc score identified 26 subjects more at high risk of thromboembolic complications in comparison to CHADS2, which was a large part of all requiring VKA (43%). According to CHADS2, these patients were qualified to moderate risk level with CHADS2 = 1. The crucial factors of high risk of TE in group II were age, female gender and vascular disease, particularly myocardial infarction.

Similar results were observed in a Danish national registry of 73,538 non-anticoagulated patients with nonvalvular AF \[[@CIT0007]\]. As in our study, a large percentage (46%) of respondents were women. They proved that CHA2DS2-VASc performed better than CHADS2 for categorization into risk groups for stroke and for identification of patients at truly low risk and that not all risk factors were associated with an equal risk of TE. A particularly high risk was associated with age ≥ 65, gender and diabetes mellitus \[[@CIT0008]\]. Opposite to our patients, the Danish population was older (31 vs. 54% ≥ 75 years), less frequently burdened with arterial hypertension (73 vs. 40%) and vascular disease (42 vs. 17%) \[[@CIT0007]\].

Similar to our results, Friberg *et al*. found that women with AF are at higher risk for ischemic stroke than men \[[@CIT0009]\]. However, in a recently published study Mikkelsen *et al*. revealed that female gender is associated with an increased risk of stroke for AF only in patients aged \> 75 years (HR 1.2, 95% CI: 1.12-1.28) \[[@CIT0010]\].

Antithrombotic therapy to prevent thromboembolism is recommended for all patients with AF, except those who are at low risk or with contraindications \[[@CIT0005]\]. Atrial fibrillation patients classified as 'low-risk' using CHADS2 score = 0 have stroke rates of 1.5% per year, so they are not 'truly low-risk'. The evidence shows that CHA2DS2-VASc score reclassifies 26% of patients with a CHADS2 score of 1 to a low risk of stroke \[[@CIT0011]\]. Therefore, CHA2DS2-VASc is better at identifying 'truly low-risk' patients with AF, who do not need any antithrombotic therapy \[[@CIT0005], [@CIT0012]\]. In our study 10% of patients had CHA2DS2-VASc = 0.

Those with a CHA2DS2-VASc score of ≥ 2 (the age-adjusted rate of stroke per year 2.2%) are at high risk of TE and should be managed with oral anticoagulation, whether with warfarin or novel oral anticoagulants that overcome the limitations or disadvantages \[[@CIT0005]\]. For those with a CHA2DS2-VASc score of 1 (the age-adjusted rate of stroke per year 1.3%), oral anticoagulation therapy with VKA or direct thrombin inhibitor, or oral factor Xa inhibitor is considered, based upon an assessment of the risk of bleeding complications and patient preferences \[[@CIT0005]\].

The decision to anticoagulate is based not only on thromboembolic risk but also on the risk of bleeding, and the European guidelines on atrial fibrillation incorporate a bleeding prediction scheme HAS-BLED to help with this decision making \[[@CIT0004], [@CIT0005]\]. It is recognized that several risk factors predisposing to bleeding are also risk factors for stroke, and although some schemas (e.g. CHADS2) have modest value for predicting stroke, they are very good at predicting a patient\'s risk of bleeding \[[@CIT0013]\].

The type and severity of comorbid disorders are the most important risk factors for anticoagulant-related bleeding. Cardiovascular disease, liver dysfunction, and severe renal impairment are associated with increased risk of bleeding \[[@CIT0014], [@CIT0015]\]. We observed only minor bleeding events, mostly from the upper respiratory (44%) and urinary tract (33%). Absence of major bleeding in our study may result from preserved renal function, especially in our younger patients (group II). In a Dutch center the most prevalent bleeding events were from the gastrointestinal tract, even 40% of all events, as major bleeding requiring a blood transfusion \[[@CIT0016]\]. Opposite to our patients, this population was older (mean age 66 vs. 73 years), less burdened with arterial hypertension (73 vs. 47%) and vascular diseases (42 vs. 11%). Similar to our study, patients received aspirin with VKA (42 vs. 39%), but less dual antiplatelet therapy (16 vs. 3.5%) \[[@CIT0016]\]. Despite the low risk of bleeding (median HAS-BLED = 1) in our population, there were several incidents of minor bleeding (13% compared to 9% in the other studies) \[[@CIT0017], [@CIT0018]\]. Possibly that can be explained by concomitant use of aspirin and antiplatelet drugs. However, in such cases in the literature there was observed more frequently major bleeding \[[@CIT0016]\].

Based on our results, it seems that some caution and regular review of the patient is needed following the initiation of antithrombotic therapy not only in the high-risk bleeding group (HAS-BLED \> 3) but also in patients with low or intermediate risk (HAS-BLED ≤ 2), particularly with concomitant use of antiplatelet drugs. Close control of INR in the therapeutic range can reduce the number of bleeding complications, as confirmed in other studies \[[@CIT0017]\].

Current practice guidelines for stroke prophylaxis recommend warfarin for patients at high risk for stroke including those over 75 years of age or younger patients with additional risk factors \[[@CIT0019]\]. Although these recommendations are strongly supported by the clinical trial evidence, studies show that many patients are not receiving appropriate VKA therapy. The approach may be changed with a new generation of anticoagulant drugs, such as dabigatran and rivaroxaban. They offer an interesting alternative to warfarin, because blood tests for monitoring INR are not required and there is lower bleeding risk while offering similar results in terms of efficacy. Their main disadvantage is the low experience of their use and no specific antidote for an overdose \[[@CIT0020]\].

The challenge is defining patients who would best benefit from thromboprophylaxis, and showing how to deliver it in the most effective and safe way. Due to the risk of bleeding complications, there is often suboptimal implementation of prevention among patients with the risk of TE. An individual approach to each patient, including risk stratification with the available scores, helps reduce the number of complications in anticoagulation.

Limitations {#S0006}
===========

The main limitation of the study is the small study group and therefore a multivariate analysis was not performed. Moreover, we analyzed data from a single academic center, and thus the strength of the evidence cannot be compared to that obtained in randomized studies. Despite these constraints, the results are consistent with other studies.

Conclusions {#S0007}
===========

The reclassifying approach with the implications of CHA2DS2-VASc and HAS-BLED schemata provides some improvement over the CHADS2 score, with the identification of real low and high risk patients. In the era of antiplatelet therapy the bleeding risk should be carefully evaluated. It seems that women present higher risk of bleeding, although less frequent use of antiplatelet therapy.
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